Terms: = Lymphoma AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Clinical Outcome
3 results:
1. DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell lymphomas.
Restelli V; Lupi M; Chilà R; Vagni M; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Damia G; Carrassa L
Mol Cancer Ther; 2019 Jul; 18(7):1255-1264. PubMed ID: 31064869
[TBL] [Abstract] [Full Text] [Related]
2. The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.
Albano F; Chiurazzi F; Mimmi S; Vecchio E; Pastore A; Cimmino C; Frieri C; Iaccino E; Pisano A; Golino G; Fiume G; Mallardo M; Scala G; Quinto I
Cell Death Dis; 2018 Jan; 9(1):13. PubMed ID: 29317636
[TBL] [Abstract] [Full Text] [Related]
3. Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
Shinozuka K; Tang H; Jones RB; Li D; Nieto Y
Biol Blood Marrow Transplant; 2016 May; 22(5):843-9. PubMed ID: 26743341
[TBL] [Abstract] [Full Text] [Related]
